16 results about "S syndrome" patented technology

The application discloses a protein zwitterionic polymer conjugate and a preparation method and application thereof. A multifunctional new medical biomaterial with mucosal adhesion, wetting, lubrication and microbial adhesion prevention is designed and synthesized, so that a new breakthrough is brought to the clinical demand of solving Sjogren's syndrome. In addition, the application has wide application prospects in the fields of oral lubrication, ophthalmic lubrication, joint repair and the like.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention belongs to the field of biodetection technology, specifically relating to early warning biomarkers for Sjögren's syndrome and their applications. The biomarkers include plasma proteins selected from LGALS9, TNFRSF9, and CD5 proteins. The AUC value of this biomarker for early prediction of Sjögren's syndrome is 0.69.

The application discloses a diagnostic marker for Sjogren's syndrome, a diagnostic device and application thereof, and relates to the technical field of Sjogren's syndrome diagnosis. The diagnostic marker for Sjogren's syndrome is selected from the markers in (1) or (2): (1) acetylcarnitine (C2); (2) C2, and at least one of the following markers: globulin concentration (G) in serum, ratio of free carnitine to acetylcarnitine (C0 / C2), decanoyl carnitine (C10), decatrienoyl carnitine (C10:3), propionyl carnitine / acetylcarnitine (C3 / C2), isovaleryl carnitine / butyryl carnitine (C5 / C4) and octanoyl carnitine / hexadecanoyl carnitine (C8 / C16). The diagnostic model constructed by single C2 has very high diagnostic efficiency for Sjogren's syndrome, and the combined use of multiple markers can further improve the diagnostic efficiency for Sjogren's syndrome.

The present invention discloses a method for the prevention or treatment of Sjögren's syndrome comprising the step of administering a prophylactic or therapeutically effective amount of N-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrole-1-yl]acetamide, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to an individual in need thereof. Equation (I)

This invention relates to the field of artificial intelligence technology and discloses a disease prediction system for primary Sjögren's syndrome based on gene polymorphism. The system consists of a gene data acquisition module, a feature processing server, an artificial intelligence prediction server, and medical and follow-up terminals. By performing quality control, functional site screening, and three-valued dose encoding on genotype data, structured gene features are constructed, and multimodal input features are generated by combining clinical phenotype and environmental exposure information. The system employs a multimodal counterfactual interpretation-Transformer model to quantify feature contributions, locate perturbation intervals, and perform counterfactual optimization inference, thereby outputting risk prediction values ​​and risk levels. This system effectively improves the accuracy and interpretability of gene polymorphism risk prediction, enables traceable and transparent risk assessment, and supports population risk identification and individualized prevention management.

Disclosed are methods for treating Jordan's syndrome in a subject in need thereof and methods of reducing at least one sign or symptom of Jordan's syndrome in a subject in need thereof. The methods comprise administering a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor to the subject. The PDE4 inhibitor may be BPN14770 and may be administered daily.

The present invention relates to crystal solid forms of relacorilant, described herein as crystalline form I and form II, methods for preparing the same, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and / or prevention of Cushing's syndrome, solid tumors or alcoholism.

Provided are a method of providing information for diagnosing Down syndrome and a method of diagnosing Down syndrome, the method comprising measuring a methylation level of a Down syndrome biomarker in a biological sample separated from a fetus, comparing the measured methylation level of the biomarker with a methylation level of the first biomarker and the second biomarker in the biological sample separated from a normal control group, and determining a presence or a risk of Down syndrome by comparing the methylation level, wherein the biomarker is a first biomarker present on chromosome 21, a second biomarker present on a chromosome other than chromosome 21, or a combination thereof. Thus, Down syndrome can be diagnosed early with high accuracy, and the disclosure is expected to be applied as a key technology in the field of Down syndrome diagnosis.

This invention discloses the application of Sjögren's syndrome biomarkers in products for diagnosing Sjögren's syndrome and a method for constructing a diagnostic model for Sjögren's syndrome, relating to the field of Sjögren's syndrome diagnostic technology. The Sjögren's syndrome biomarker includes the Val to Phe ratio. The diagnostic model established based on this single biomarker has an AUC value greater than 0.9 on its ROC curve, exhibiting extremely high diagnostic specificity, sensitivity, and accuracy. Combinations of this biomarker with other biomarkers also demonstrate extremely high diagnostic efficacy. Therefore, the Sjögren's syndrome diagnostic biomarkers provided by this invention have promising application prospects in the diagnosis of Sjögren's syndrome.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).